[Vasodilators in heart failure. Basis for their use].
Mesquita
E T
ET
Instituto do Coração do Hospital das Clínicas, FMUSP.
Mady
C
C
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D017079:Exercise Tolerance / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D015221:Potassium Channels / Q000819:agonists; D013318:Stroke Volume / Q000187:drug effects; D013566:Sympathomimetics / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D017725:Ventricular Pressure / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D015259:Dopamine Agents; D010726:Phosphodiesterase Inhibitors; D015221:Potassium Channels; D013566:Sympathomimetics; D014665:Vasodilator Agents